A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL)

Trial Profile

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Cerdulatinib (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Portola Pharmaceuticals
  • Most Recent Events

    • 01 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Jul 2018.
    • 01 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2018.
    • 12 Dec 2017 Results from phase I part of the study assessing PK/PD relationships and associations with tumor response, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top